165 related articles for article (PubMed ID: 23216077)
21. Hepatocellular adenoma classification: a comparative evaluation of immunohistochemistry and targeted mutational analysis.
Margolskee E; Bao F; de Gonzalez AK; Moreira RK; Lagana S; Sireci AN; Sepulveda AR; Remotti H; Lefkowitch JH; Salomao M
Diagn Pathol; 2016 Mar; 11():27. PubMed ID: 26961851
[TBL] [Abstract][Full Text] [Related]
22. Chromosomal and genetic alterations in human hepatocellular adenomas associated with type Ia glycogen storage disease.
Kishnani PS; Chuang TP; Bali D; Koeberl D; Austin S; Weinstein DA; Murphy E; Chen YT; Boyette K; Liu CH; Chen YT; Li LH
Hum Mol Genet; 2009 Dec; 18(24):4781-90. PubMed ID: 19762333
[TBL] [Abstract][Full Text] [Related]
23. Expression of potential beta-catenin targets, cyclin D1, c-Jun, c-Myc, E-cadherin, and EGFR in chemically induced hepatocellular neoplasms from B6C3F1 mice.
Anna CH; Iida M; Sills RC; Devereux TR
Toxicol Appl Pharmacol; 2003 Jul; 190(2):135-45. PubMed ID: 12878043
[TBL] [Abstract][Full Text] [Related]
24. ER-α36, a novel variant of ER-α, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway.
Tong JS; Zhang QH; Wang ZB; Li S; Yang CR; Fu XQ; Hou Y; Wang ZY; Sheng J; Sun QY
PLoS One; 2010 Nov; 5(11):e15408. PubMed ID: 21079811
[TBL] [Abstract][Full Text] [Related]
25. Hepatocellular adenomas: review of pathological and molecular features.
Beaufrère A; Paradis V
Hum Pathol; 2021 Jun; 112():128-137. PubMed ID: 33307077
[TBL] [Abstract][Full Text] [Related]
26. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer.
Shi L; Dong B; Li Z; Lu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Wang Z; Xie Y
J Clin Oncol; 2009 Jul; 27(21):3423-9. PubMed ID: 19487384
[TBL] [Abstract][Full Text] [Related]
27. Molecular classification of hepatocellular adenoma in clinical practice.
Nault JC; Paradis V; Cherqui D; Vilgrain V; Zucman-Rossi J
J Hepatol; 2017 Nov; 67(5):1074-1083. PubMed ID: 28733222
[TBL] [Abstract][Full Text] [Related]
28. Decoding cell death signals in liver inflammation.
Brenner C; Galluzzi L; Kepp O; Kroemer G
J Hepatol; 2013 Sep; 59(3):583-94. PubMed ID: 23567086
[TBL] [Abstract][Full Text] [Related]
29. Autophagy-deficient mice develop multiple liver tumors.
Takamura A; Komatsu M; Hara T; Sakamoto A; Kishi C; Waguri S; Eishi Y; Hino O; Tanaka K; Mizushima N
Genes Dev; 2011 Apr; 25(8):795-800. PubMed ID: 21498569
[TBL] [Abstract][Full Text] [Related]
30. Hepatocellular adenomas in a large community population, 2000 to 2010: reclassification per current World Health Organization classification and results of long-term follow-up.
Shafizadeh N; Genrich G; Ferrell L; Kakar S
Hum Pathol; 2014 May; 45(5):976-83. PubMed ID: 24746201
[TBL] [Abstract][Full Text] [Related]
31. Argininosuccinate synthase 1 (ASS1): A marker of unclassified hepatocellular adenoma and high bleeding risk.
Henriet E; Abou Hammoud A; Dupuy JW; Dartigues B; Ezzoukry Z; Dugot-Senant N; Leste-Lasserre T; Pallares-Lupon N; Nikolski M; Le Bail B; Blanc JF; Balabaud C; Bioulac-Sage P; Raymond AA; Saltel F
Hepatology; 2017 Dec; 66(6):2016-2028. PubMed ID: 28646562
[TBL] [Abstract][Full Text] [Related]
32. Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha.
Shi YE; Chen Y; Dackour R; Potters L; Wang S; Ding Q; Wang Z; Liu YE
Am J Pathol; 2010 Aug; 177(2):964-73. PubMed ID: 20595634
[TBL] [Abstract][Full Text] [Related]
33. Subtype classification of hepatocellular adenoma.
Bioulac-Sage P; Balabaud C; Zucman-Rossi J
Dig Surg; 2010; 27(1):39-45. PubMed ID: 20357450
[TBL] [Abstract][Full Text] [Related]
34. Unique genetic alterations and clinicopathological features of hepatocellular adenoma in Chinese population.
Liu HP; Zhao Q; Jin GZ; Qian YW; Gu YJ; Dong H; Lu XY; Cong WM; Wu MC
Pathol Res Pract; 2015 Dec; 211(12):918-24. PubMed ID: 26608415
[TBL] [Abstract][Full Text] [Related]
35. Hepatocellular adenoma: An unsolved diagnostic enigma.
Renzulli M; Clemente A; Tovoli F; Cappabianca S; Bolondi L; Golfieri R
World J Gastroenterol; 2019 May; 25(20):2442-2449. PubMed ID: 31171888
[TBL] [Abstract][Full Text] [Related]
36. Does Argininosuccinate Synthase 1 (ASS1) Immunohistochemistry Predict an Increased Risk of Hemorrhage for Hepatocellular Adenomas?
Lehrke HD; Van Treeck BJ; Allende D; Denham LJ; Gonzalez RS; Moreira RK; Mounajjed T; Naini BV; Smoot RL; Zreik RT; Jenkins S; Graham RP
Appl Immunohistochem Mol Morphol; 2020 Jul; 28(6):464-470. PubMed ID: 31135443
[TBL] [Abstract][Full Text] [Related]
37. Hepatocyte nuclear factor-1 α inactivated hepatocellular adenomas in patient with congenital absence of the portal vein: a case report.
Tateishi Y; Furuya M; Kondo F; Torii I; Nojiri K; Tanaka Y; Umeda S; Okudela K; Inayama Y; Endo I; Ohashi K
Pathol Int; 2013 Jul; 63(7):358-63. PubMed ID: 23865574
[TBL] [Abstract][Full Text] [Related]
38. Endoplasmic reticulum stress-activated glycogen synthase kinase 3β aggravates liver inflammation and hepatotoxicity in mice with acute liver failure.
Ren F; Zhou L; Zhang X; Wen T; Shi H; Xie B; Li Z; Chen D; Wang Z; Duan Z
Inflammation; 2015; 38(3):1151-65. PubMed ID: 25630719
[TBL] [Abstract][Full Text] [Related]
39. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry.
Bioulac-Sage P; Rebouissou S; Thomas C; Blanc JF; Saric J; Sa Cunha A; Rullier A; Cubel G; Couchy G; Imbeaud S; Balabaud C; Zucman-Rossi J
Hepatology; 2007 Sep; 46(3):740-8. PubMed ID: 17663417
[TBL] [Abstract][Full Text] [Related]
40. Changing trends in malignant transformation of hepatocellular adenoma.
Farges O; Ferreira N; Dokmak S; Belghiti J; Bedossa P; Paradis V
Gut; 2011 Jan; 60(1):85-9. PubMed ID: 21148580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
